RaQualia Pharma Inc.

Tokyo Stock Exchange:4579.T

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

🐶 Pet Food

💊 Pharmaceuticals

Location

Japan

Market Cap

USD 94.61 M

Share Price

USD 3.87

Avg Daily Volume

298,219

Change (1 day)

-3.81%

Change (1 year)

-0.54%

Change (YTD)

58.29%

RaQualia Pharma Inc. Accounts Payable for the year ending December 31, 2024: USD 377.26 K

RaQualia Pharma Inc. Accounts Payable is USD 377.26 K for the year ending December 31, 2024, a -1.74% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.

RaQualia Pharma Inc. Accounts Payable for the year ending December 31, 2023 was USD 383.93 K, a -60.68% change year over year.
RaQualia Pharma Inc. Accounts Payable for the year ending December 31, 2022 was USD 976.38 K, a 144.39% change year over year.
RaQualia Pharma Inc. Accounts Payable for the year ending December 31, 2021 was USD 399.52 K, a -1.30% change year over year.
RaQualia Pharma Inc. Accounts Payable for the year ending December 31, 2020 was USD 404.79 K, a 28.29% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Accounts Payable	Short-Term Debt	Long-Term Debt	Total Liabilities

Tokyo Stock Exchange: 4579.T

RaQualia Pharma Inc.

CEO	Masaki Sudo
IPO Date	July 20, 2011
Location	Japan
Headquarters	Meieki Southside Square
Employees	64
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 🐶 Pet Food 💊 Pharmaceuticals

Description

RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I clinical trial in China, as well as in phase I clinical trial in China and the United States to treat cancer. The company also provides veterinary products such as, grapiprant for osteoarthritis in dogs; ghrelin receptor agonist to treat cancer-related anorexia/cachexia syndrome, and constipation resulting from spinal cord injury; and ELURA, a drug for the management of weight loss in cats with chronic kidney disease. In addition, it provides TRPM8 blocker for the target indication of neuropathic pain; motilin receptor agonist to treat gastrointestinal dysmotility, including gastroparesis, functional dyspepsia, and post-operative ileus; potassium-competitive acid blocker to treat gastro-esophageal reflux disease that has completed phase 1 clinical trial; 5-HT4 partial agonist to treat gastroparesis, functional dyspepsia, and chronic constipation; 5-HT2B antagonist to treat irritable bowel syndrome with diarrhea; EP4 antagonist, a pain management drugs for dogs; serotonin 5-HT2A and dopamine D2 receptor blocker to treat schizophrenia; EP4 antagonist to treat cancer that is in phase I clinical trial, as well as in phase 1 clinical trial for the indication of pain; Cyclooxygenase-2 inhibitor, Phase I clinical trials for the indication of pain; CB2 agonist; selective sodium channel blocker; P2X7 receptor antagonist, which is in Phase I clinical trials for the target indication of neuropathic pain; and retinoic acid receptor alpha agonist. It has a collaborative agreement with Interprotein Corporation, ASKA Pharmaceutical. Co., Ltd., and Epigeneron, Inc. The company was incorporated in 2008 and is headquartered in Nagoya, Japan.